Imatinib EP Impurity CQ: What is Imatinib EP Impurity C Q: What is the CAS Number of Imatinib EP Impurity C
- CAS1820893-54-6
- CatalogueRS-I027267
- FormulaC37H50F4N8O5
- MW762.8
On this page
Custom synthesis — structure on request
Product identification
| Product name | Imatinib EP Impurity CQ: What is Imatinib EP Impurity C Q: What is the CAS Number of Imatinib EP Impurity C |
|---|---|
| Catalogue No. | RS-I027267 |
| CAS No. | 1820893-54-6 |
| Molecular formula | C37H50F4N8O5 |
| Molecular weight | 762.8 |
| Exact mass | 762.3840 (monoisotopic) |
| Availability | Back order— restocking can be arranged, about 1–2 weeks |
| Standard type | Reference Standards |
| Drug substance | Imatinib |
| Storage | Refer to the certificate of analysis (COA) supplied with each lot |
| Intended use | For laboratory and research use only. Not for human or veterinary use. |
What is stated on the certificate
Content and purity are assigned per lot and stated on the certificate of analysis issued for the batch you receive — they are not a catalogue-level figure. The certificate records the tests performed, the specification applied and the result obtained for that lot.
| Field | Basis |
|---|---|
| Identity | Spectroscopic and chromatographic methods appropriate to the material |
| Purity | Chromatographic purity, area normalisation unless stated otherwise |
| Assay / content | Mass balance, corrected for the stated volatiles and residue |
| Catalogue and batch numbers | RS-I027267 / batch number on the certificate |
| Retest date | Printed on the certificate for the lot supplied |
Frequently asked
What documentation is supplied with this lot?
Is the assigned value given on an “as is” basis?
How should this material be stored?
Do you supply pack sizes other than those listed?
Finding this standard
Buyers reach this compound by CAS number, by catalogue number, through the drug substance it belongs to, or through the type of standard it is. Those routes all start here:
- Other impurities of Imatinib
- Standards by type (all categories)
- Documents for this item (COA, SDS)
- Certificate of analysis for RS-I027267
- Request a quotation for RS-I027267
Searching another way? Send the structure, a SMILES string or the pharmacopoeial name — a CAS number is not required for a non-compendial impurity. Write to sales@rssechem.com.
Other standards of Imatinib
All 103 further standards are on this page — 20 shown at first, then 20 more per click on Load more.
Imatinib
IN STOCKRS-U011044Imatinib hydrochloride
BACK ORDERRS-U011A04Imatinib EP Impurity A
IN STOCKRS-Z395ULRImatinib EP Impurity B
IN STOCKRS-I027037Imatinib EP Impurity B(HCl Salt)
BACK ORDERRS-I027038Imatinib EP Impurity C
IN STOCKRS-I027032Imatinib EP Impurity C (HCl Salt)
BACK ORDERRS-I027027Imatinib EP Impurity F
IN STOCKRS-I027014Imatinib Impurity E
IN STOCKRS-I027012Imatinib Impurity F
IN STOCKRS-I027004Imatinib Impurity K
BACK ORDERRS-I027044Imatinib Impurity L
IN STOCKRS-I027035Imatinib Mesylate-Impurity G (Dihydrochloride)
CUSTOM SYNTHESISRS-Z401I5Q(2E)-3-(Dimethylamino)-1-pyridin-4-ylprop-2-en-1-one
IN STOCKRS-I006187(E)-3-(Dimethylamino)-1-(pyridin-4-yl)prop-2-en-1-one
CUSTOM SYNTHESISRS-Z395ULS1-(2-Methyl-5-nitrophenyl)biguanide Hydrochloride
BACK ORDERRS-U0108091-(4-Cyanobenzyl)piperazine
CUSTOM SYNTHESISRS-U006AAS1821122-73-9 (free base);
BACK ORDERRS-I0270612-(4-Methylpiperazin-1-ylmethyl)benzoic Acid
CUSTOM SYNTHESISRS-U0106632-Toluidine-d7
IN STOCKRS-I1182533-((4-Methylpiperazin-1-yl)methyl)benzoic acid hydrochloride
IN STOCKRS-U053287Imatinib EP Impurity A
IN STOCKRS-I0103213-Acetylpyridine N-Oxide
IN STOCKRS-P0182964-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride Dichydrochloride
IN STOCKRS-Z393OMN4-(4-Methylpiperazin-1-ylmethyl)benzoylchloride
IN STOCKRS-I0270584-(4-Methylpiperazinylmethyl)benzamide
IN STOCKRS-U211OVP4-(Chloromethyl)benzoic acid
CUSTOM SYNTHESISRS-U0061944-(Dimethoxymethyl)benzoic Acid
IN STOCKRS-P0062554-(Piperazin-1-ylmethyl)benzoic acid dihydrochloride
IN STOCKRS-Z401LJD4-Des[(4-Methyl-1-piperazinyl)methyl]-4-formyl Imatinib
BACK ORDERRS-U0680614-Methyl-3-(trifluoromethyl)benzoic Acid
IN STOCKRS-Z401GJ56-Methyl-N1-(4-methyl-6-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
IN STOCKRS-D003046Butyl methanesulfonate
IN STOCKRS-C004039Genfatinib-d3 (Imatinib-d3)
IN STOCKRS-I117003Gleevec-d8 Mesylate (Imatinib-d8 Mesylate)
BACK ORDERRS-I027020Imatinib Carbaldehyde
BACK ORDERRS-I027052Imatinib Carboxylic Impurity
IN STOCKRS-Z393OMMImatinib D4
BACK ORDERRS-I027053Imatinib Diamine N1-Formyl N3-Methyl Impurity
IN STOCKRS-I027069Imatinib Impurity BY
IN STOCKRS-I027016Imatinib Impurity XT
IN STOCKRS-I027041Imatinib Para-diaminomethylbenzene Impurity-d3
CUSTOM SYNTHESISRS-I027022Imatinib Regioisomer 2
BACK ORDERRS-I027068Isopropyl methanesulfonate
IN STOCKRS-C032031Methyl 4-(Hydroxymethyl)cyclohexanecarboxylate
BACK ORDERRS-U082244METHYL TRANS-4-HYDROXYMETHYLCYCLOHEXANECARBOXYLATE
IN STOCKRS-Z397HH5N-(4-Methyl-3-aminophenyl)-4-(4-methylpiperazinomethyl)benzamide
CUSTOM SYNTHESISRS-U096833N-Boc-N-Desmethyl Imatinib
BACK ORDERRS-I027003N-Boc-N-methylpiperazine-d8
IN STOCKRS-I091035Imatinib EP Impurity C (Mesylate Salt)
IN STOCKRS-I027050N-Desmethyl Imatinib-[D8]
IN STOCKRS-I091026o-Toluidine
IN STOCKRS-U018108p-Toluic acid
IN STOCKRS-C006056Piperazinium, 1,4-bis[(4-carboxyphenyl)methyl]-1-methyl-, hydrochloride (1:2)
BACK ORDERRS-Z398OVMtert-Butyl 4-(4-(methoxycarbonyl)benzyl)piperazine-1-carboxylate
IN STOCKRS-U107939Imatinib Impurity 2
BACK ORDERRS-I001BSHImatinib Impurity 11
BACK ORDERRS-I001B85Imatinib Impurity 15
IN STOCKRS-I027018Imatinib Impurity 16
IN STOCKRS-I027013Imatinib Impurity 25
CUSTOM SYNTHESISRS-I001AULImatinib Impurity 26 (6232-88-8)
IN STOCKRS-I027054Imatinib Impurity 29
IN STOCKRS-I001BLTImatinib Impurity 32
IN STOCKRS-I027015Imatinib Impurity 34
CUSTOM SYNTHESISRS-I027063Imatinib Impurity 38
IN STOCKRS-I027002Imatinib Impurity 39 (796738-71-1)
IN STOCKRS-I027055Imatinib Impurity 44
CUSTOM SYNTHESISRS-I001B8HImatinib Impurity 44
BACK ORDERRS-I027001Imatinib Impurity 45
BACK ORDERRS-I027010Imatinib Impurity 46
IN STOCKRS-I027023Alogliptin Related Compound 47
IN STOCKRS-Z401KFKImatinib Impurity 47
IN STOCKRS-I027017Imatinib Impurity 52
IN STOCKRS-I027033Imatinib Impurity 53
BACK ORDERRS-I027011Imatinib Impurity 62 (314268-40-1)
IN STOCKRS-I027059Imatinib Impurity 72
BACK ORDERRS-I027154Imatinib Impurity 77
IN STOCKRS-Z400HEYImatinib Impurity 81 HCl
IN STOCKRS-I027046Imatinib Impurity 90
IN STOCKRS-I027057Imatinib Impurity 110
IN STOCKRS-I027056Imatinib N-Oxide Impurity 117
BACK ORDERRS-I027067Imatinib Impurity 124
CUSTOM SYNTHESISRS-I027006Imatinib Impurity 125
IN STOCKRS-I027008Imatinib Impurity 126
IN STOCKRS-I027021Imatinib EP Impurity D
IN STOCKRS-I027028Imatinib Impurity 128
IN STOCKRS-I027034Imatinib Impurity 129
IN STOCKRS-I027036Imatinib Impurity 130
BACK ORDERRS-I027045Imatinib Impurity 134
IN STOCKRS-I027062Imatinib Impurity 152
CUSTOM SYNTHESISRS-I027005Imatinib Impurity 154
IN STOCKRS-I027024Imatinib Impurity 155
IN STOCKRS-I027025Imatinib Impurity 156
IN STOCKRS-I027026Imatinib Impurity 158
IN STOCKRS-I027031Imatinib Impurity 159
CUSTOM SYNTHESISRS-I027039Imatinib Impurity 160
CUSTOM SYNTHESISRS-I027040Imatinib Impurity 161
IN STOCKRS-I027042Imatinib Impurity 162
IN STOCKRS-I027043Imatinib Impurity 163
IN STOCKRS-I027048Imatinib Impurity 164
CUSTOM SYNTHESISRS-I027049Imatinib Impurity 185
IN STOCKRS-U010446Imatinib Impurity 186
IN STOCKRS-I027064
Pharmacopoeial names (EP, USP, BP, JP) are used for identification purposes only and do not imply endorsement by those bodies. This product is supplied for laboratory and research use only — not for human or veterinary use.



























![Chemical structure of 4-Des[(4-Methyl-1-piperazinyl)methyl]-4-formyl Imatinib](/structures/w4/HCRUWADOEOYZDU-UHFFFAOYSA-N.webp?v=11)




















![Chemical structure of N-Desmethyl Imatinib-[D8]](/structures/w4/BQQYXPHRXIZMDM-DBVREXLBSA-N.webp?v=11)


![Chemical structure of Piperazinium, 1,4-bis[(4-carboxyphenyl)methyl]-1-methyl-, hydrochloride (1:2)](/structures/w4/BZOOLSOBIOUCBW-UHFFFAOYSA-O.webp?v=11)















































